Clinical Trials Directory

Trials / Unknown

UnknownNCT01632124

Rituximab-induced Pulmonary Function Changes

Rituximab-induced Pulmonary Function Changes - an Observational Study in Patients With Rheumatoid Arthritis and Inflammatory Myositis

Status
Unknown
Phase
Study type
Observational
Enrollment
80 (estimated)
Sponsor
University of Zurich · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Measuring lung function (FVC, FEV1, DLCO) before, during and after treatment with rituximab in patients with rheumatoid arthritis or inflammatory myositis.

Detailed description

The objective of this study is to investigate whether rituximab (RTX), a drug commonly prescribed in patients with rheumatoid arthritis (RA) or inflammatory myositis, is associated with subclinical interstitial lung disease (ILD). Surrogate markers for interstitial lung diseases are a decrease of the forced vital capacity (FVC) and/or the diffusing capacity of the lung for carbon monoxide (DLCO). However, the measurement of these lung function parameters is indicated as regular follow-up examinations during the treatment with RTX according to the principles of "good clinical practice". We will perform pulmonary function testing (spirometry) including measurement of the DLCO in patients with RA, who are going to be treated with RTX. A baseline lung function measurement will be performed immediately before RTX therapy is started. Follow-up measurements will be performed at 2 weeks, 4 weeks, 8 weeks and 6 months after initiation of RTX therapy. A reduction in forced vital capacity (FVC) of \>10% or a fall of \>15% in DLCO will be defined as indicative for ILD.

Conditions

Interventions

TypeNameDescription
OTHERLung function measurementSpirometry and measurement of diffusing capacity for carbon monoxide

Timeline

Start date
2012-01-01
Primary completion
2013-12-01
Completion
2013-12-01
First posted
2012-06-29
Last updated
2012-06-29

Locations

1 site across 1 country: Switzerland

Source: ClinicalTrials.gov record NCT01632124. Inclusion in this directory is not an endorsement.